Panacea Biotec Ltd logo

Panacea Biotec Ltd

PANACEABIO NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹2,583 Cr
Volatility
Moderate
P/E Ratio
-353.9
EBITDA
₹-4.66 Cr
Return on Equity
-1.05%
Debt to Equity
0.03
Book Value
₹136.3
52W High
₹647
52W Low
₹292.4

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Panacea Biotec Ltd insights

35 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

6
  • Stock is trading at 2.91 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 0.47% over past five years.
  • Company has a low return on equity of -3.48% over last 3 years.
  • Earnings include an other income of Rs.26.4 Cr.
  • Company's cost of borrowing seems high

Growth Rate

Revenue Growth
10.34% ↘
Net Income Growth
-10.34% ↘
Cash Flow Change
-27270.00% ↘
ROE
483.33% ↗
ROCE
-181.48% ↗
EBITDA Margin (Avg.)
-24.18% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 39d ago
AI opinion · based on fundamentals
Risk high

Panacea Biotec Ltd is a healthcare company with a market cap of Rs.3,437 Cr that remains loss-making with a negative PE of -469.7x and negative 3-year average ROE of -3%. While the stock has delivered a strong 63% CAGR over 3 years and TTM profit growth of 52%, the underlying business has posted near-zero sales growth over 5 and 10 years.

Bull Case 7
  • Stock has delivered a 3-year CAGR of 63%, significantly outperforming broader markets
  • TTM compounded profit growth of 52% indicates a sharp recent improvement in earnings trajectory
  • Company is almost debt free, reducing balance sheet risk and interest burden
  • 3-year compounded profit growth of 21% shows a sustained recovery trend in profitability
  • TTM sales growth of 14% marks a notable acceleration after years of stagnant revenue
  • 10-year stock CAGR of 16% shows long-term wealth creation despite operational challenges
  • 5-year compounded profit growth of 13% suggests the turnaround has been building over multiple years
Bear Case 8
  • Negative PE ratio of -469.7x indicates the company is still loss-making at the net level
  • 3-year average ROE of -3% and last year ROE of -2% show persistent inability to generate returns on equity
  • 5-year compounded sales growth of just 0.47% reflects near-complete revenue stagnation over a long period
  • Stock trades at 4.03x book value despite negative earnings, suggesting stretched valuations relative to fundamentals
  • Other income of Rs.36.4 Cr inflates reported earnings, masking weak core operating performance
  • Zero dividend yield means shareholders receive no income return while bearing equity risk
  • Company has low interest coverage ratio despite being nearly debt free, indicating weak operating profits
  • High cost of borrowing suggests lenders perceive elevated credit risk in the business

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 39d ago
Headwinds 3
  • Stock crashes 9.99% on heavy volume Jun 10

    Panacea Biotec fell 9.99% to ₹547.65 on Jun 10 with 1.52 lakh shares traded, double the monthly average of 75,434 shares, leading BSE 'B' group losers.

  • Widening losses and going concern risk Jun 9

    FY26 standalone losses widened to ₹28.74 crore from ₹15.18 crore YoY, with negative retained earnings of ₹217.82 crore raising going concern uncertainty.

  • Stock still 70% below 2021 highs Jun 9

    Despite the recent rally, the stock had fallen almost 70% from its 2021 levels before the recent recovery, indicating long-term underperformance.

Positives 5
  • DENSTAR dengue vaccine project launched Jun 8

    Panacea Biotec launched the EU-funded €11.1 million DENSTAR project on Jun 1, 2026 to fast-track DengiAll licensure across 54 African nations with a 10-partner consortium from 9 countries.

  • Stock surges 60% in six sessions Jun 9

    Shares surged 60% in six trading days from ₹398.45 on Jun 1 to a 52-week high of ₹637.70, with trading volumes jumping over five-fold and 9.95 million shares (16% of equity) changing hands.

  • DengiAll single-dose vaccine advantages Jun 9

    DengiAll requires no prior blood testing, is a single-dose cost-efficient tetravalent vaccine targeting all four dengue serotypes, making it scalable for mass rollout in low- and middle-income nations.

  • Phase III trials progressing in India Jun 9

    Panacea Biotec is conducting a Phase III trial of DengiAll in India in collaboration with ICMR across 19 sites in 18 states, with enrollments completed in April 2026.

  • Vaccine division revenue up 12% YoY Jun 8

    The company reported 12% YoY revenue growth in its vaccine division in May 2026, with higher long-term business orders from key institutional customers.

Neutral 1
  • DENSTAR consortium structure detailed Jun 8

    The four-year DENSTAR project is coordinated by Italy's Sclavo Vaccines Association and includes Johns Hopkins, NIAID, and research organizations in Ghana, Gabon, Mozambique, and DRC, with Phase I/III trials planned in African adults and children.

TL;DR: Panacea Biotec is riding strong momentum from its EU-funded DENSTAR dengue vaccine project, which drove a 60% rally in six sessions to 52-week highs. The DengiAll platform offers genuine first-mover advantages in underserved tropical markets with its single-dose, no-blood-test design. However, the sharp 9.99% correction on Jun 10 after such a parabolic move, combined with widening standalone losses and going concern flags, suggests high volatility ahead. The trend is improving on the vaccine pipeline narrative, but execution risk remains elevated given the company's weak financials and the four-year timeline to African licensure.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
129
143
151
136
116
147
163
133
167
141
165
167
200
Expenses
140
147
151
143
130
140
156
159
168
159
153
164
194
Operating Profit
-10.31
-3.56
-0.15
-6.04
-13.99
7
7.96
-26.88
-1.18
-17.79
11.74
2.57
5.67
OPM %
-7.98%
-2.49%
-0.1%
-4.43%
-12.09%
4.75%
4.87%
-20.28%
-0.71%
-12.61%
7.11%
1.54%
2.84%
Other Income
33.82
6
8.46
13.55
6.54
7.42
6.39
36.3
16.99
9.1
5.05
5.26
6.98
Interest
1
0.91
0.85
0.82
0.87
0.98
0.99
1.04
0.86
2.14
1.85
1.2
1.18
Depreciation
9.48
9.31
9.11
8.81
8.73
8.68
8.98
8.42
8.39
8.34
8.45
7.88
7.9
PBT
13.03
-7.78
-1.65
-2.12
-17.05
4.76
4.38
-0.04
6.56
-19.17
6.49
-1.25
3.57
Tax %
15.73%
6.56%
33.33%
-6.13%
-6.86%
1.05%
-1.37%
4875%
39.63%
-26.92%
40.06%
-20%
38.38%
Net Profit
10.98
-8.29
-2.2
-1.99
-15.88
4.71
4.44
-1.99
3.96
-14.01
3.89
-1
2.2
EPS in Rs
1.79
-1.35
-0.37
-0.32
-2.58
0.78
0.74
-0.31
0.66
-2.27
0.65
0.08
0.38
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
687
653
544
593
457
544
625
661
460
559
559
640
673
Expenses
643
541
505
509
591
484
548
674
558
579
584
644
670
Operating Profit
44
112
39
84
-134
60
77
-13
-98
-20
-25
-5
2
OPM %
6%
17%
7%
14%
-29%
11%
12%
-2%
-21%
-3.5%
-4.4%
-0.7%
0.3%
Other Income
28
70
62
8
338
-21
9
1,687
154
62
55
36
26
Interest
105
127
101
101
105
174
185
181
4
4
4
6
6
Depreciation
67
73
68
57
54
43
46
44
39
37
35
33
33
PBT
-99
-19
-67
-66
45
-178
-146
1,449
13
1
-8
-7
-10
Tax %
3%
10%
-16%
15%
17%
9%
1%
26%
363%
201%
10%
-3%
—
Net Profit
-108
-21
-56
-76
38
-194
-148
1,078
-34
-2
-9
-7
-9
EPS in Rs
-17.38
-2.98
-8.89
-12.07
6.15
-31.69
-24.09
176
-5.42
-0.19
-1.37
-0.88
-1.16
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
6
6
6
6
6
6
6
Reserves
449
426
350
303
344
193
-235
871
837
836
829
829
Borrowings
1,111
1,105
994
941
646
742
820
34
20
21
22
24
Other Liabilities
364
317
440
349
379
449
587
848
407
378
433
404
Total Liabilities
1,930
1,854
1,789
1,598
1,376
1,390
1,178
1,759
1,271
1,241
1,290
1,262
Fixed Assets
1,144
1,071
1,001
949
806
657
609
622
600
582
567
620
CWIP
155
161
30
40
23
24
34
17
42
102
128
100
Investments
15
9
7
7
5
6
0
5
13
40
3
10
Other Assets
616
614
750
602
542
703
534
1,114
615
517
592
532
Total Assets
1,930
1,854
1,789
1,598
1,376
1,390
1,178
1,759
1,271
1,241
1,290
1,262
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
37
91
131
118
105
-30
107
-108
-422
0
-27
17
Investing
-37
16
-26
55
-6
-35
-48
1,283
430
10
65
-40
Financing
-1
-117
-107
-164
-101
91
-47
-1,176
-18
-3
-3
-1
Net Cash Flow
-1
-10
-2
9
-2
26
12
-2
-10
7
35
-25
Free Cash Flow
30
85
107
103
100
-21
89
-119
-424
-71
-77
-37
CFO/OP
96
64
320
146
-77
-36
141
-2,235
429
-12
108
-496
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
79
95
84
71
46
49
45
48
37
47
42
Inventory Days
404
516
770
651
173
344
311
296
292
282
391
251
Days Payable
272
318
607
540
572
463
440
327
256
244
413
247
Cash Conversion Cycle
184
278
259
195
-328
-73
-80
14
83
76
25
46
Working Capital Days
-126
27
-46
-96
-363
93
-43
-229
-5
-2
44
57
ROCE %
0%
4%
2%
3%
-16%
5%
5%
-6%
-10%
-4%
-5%
-2%

Shareholding Pattern

As of Jun 2026
Promoters 72.48%
Public 15.54%
Others 7.42%
FIIs 2.31%
DIIs 2.25%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.59%
73.46%
72.87%
72.49%
72.48%
72.48%
72.48%
72.48%
72.48%
72.48%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.27%
0.27%
0.37%
0.38%
1.16%
0.78%
1.06%
1.36%
1.60%
2.31%
DIIs
1.27%
0.00%
0.00%
0.00%
0.00%
0.00%
0.29%
0.43%
0.43%
0.54%
0.00%
0.00%
0.84%
1.07%
1.16%
1.17%
1.49%
1.52%
1.81%
1.85%
1.97%
2.25%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
17.34%
15.21%
15.57%
15.99%
15.14%
15.60%
15.79%
15.97%
15.82%
16.15%
19.20%
19.63%
19.90%
20.42%
18.11%
18.98%
18.45%
18.17%
17.69%
17.49%
16.81%
15.54%
Others
7.80%
11.20%
10.84%
10.42%
11.27%
10.81%
10.33%
10.02%
10.16%
9.73%
7.21%
6.78%
5.40%
4.79%
7.49%
6.99%
6.41%
7.05%
6.96%
6.81%
7.15%
7.42%
No. of Shareholders
27,228
54,313
52,816
52,465
49,563
49,896
49,078
50,533
48,634
47,815
48,878
47,091
46,242
45,513
39,982
35,446
33,593
34,256
33,593
34,597
32,620
33,532

Documents

Frequently Asked Questions about Panacea Biotec Ltd

What does Panacea Biotec Ltd do?
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
Where is Panacea Biotec Ltd (PANACEABIO) listed?
Panacea Biotec Ltd is listed on the Indian stock exchanges. It is listed on NSE: PANACEABIO and BSE: 531349. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Panacea Biotec Ltd belong to?
Panacea Biotec Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Panacea Biotec Ltd?
Panacea Biotec Ltd has a market capitalisation of approximately ₹2582.94 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Panacea Biotec Ltd?
The Price-to-Earnings (PE) ratio of Panacea Biotec Ltd is -353.90. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Panacea Biotec Ltd?
Over the past 52 weeks, Panacea Biotec Ltd has traded between a low of ₹292.4 and a high of ₹647. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Panacea Biotec Ltd?
Panacea Biotec Ltd has a Return on Equity (ROE) of -1.05%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Panacea Biotec Ltd on Tapetide?
On Tapetide, you can view Panacea Biotec Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]

Website panaceabiotec.com
CEO Dr. Rajesh Jain Ph.D.
Employees 2,149
Listed 1996-04-17
Face Value ₹ 1
Issued Size 6,12,50,746

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List